[go: up one dir, main page]

HUE053778T2 - Oxiszterinek és ezek alkalmazása - Google Patents

Oxiszterinek és ezek alkalmazása

Info

Publication number
HUE053778T2
HUE053778T2 HUE16821924A HUE16821924A HUE053778T2 HU E053778 T2 HUE053778 T2 HU E053778T2 HU E16821924 A HUE16821924 A HU E16821924A HU E16821924 A HUE16821924 A HU E16821924A HU E053778 T2 HUE053778 T2 HU E053778T2
Authority
HU
Hungary
Prior art keywords
oxysterols
methods
Prior art date
Application number
HUE16821924A
Other languages
English (en)
Inventor
Francesco G Salituro
Albert Jean Robichaud
Botella Gabriel Martinez
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of HUE053778T2 publication Critical patent/HUE053778T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE16821924A 2015-07-06 2016-07-06 Oxiszterinek és ezek alkalmazása HUE053778T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189048P 2015-07-06 2015-07-06
US201662280394P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
HUE053778T2 true HUE053778T2 (hu) 2021-07-28

Family

ID=57686105

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16821924A HUE053778T2 (hu) 2015-07-06 2016-07-06 Oxiszterinek és ezek alkalmazása

Country Status (30)

Country Link
US (4) US10201550B2 (hu)
EP (3) EP3828194B1 (hu)
JP (4) JP2018519351A (hu)
KR (2) KR20240137111A (hu)
CN (2) CN108135912B (hu)
AU (3) AU2016289967B2 (hu)
BR (2) BR112018000129B1 (hu)
CA (1) CA2991214C (hu)
CO (1) CO2018000660A2 (hu)
CY (1) CY1124496T1 (hu)
DK (2) DK3319611T3 (hu)
ES (2) ES3035617T3 (hu)
FI (1) FI3828194T3 (hu)
HR (1) HRP20210526T8 (hu)
HU (1) HUE053778T2 (hu)
IL (2) IL256710B2 (hu)
LT (1) LT3319611T (hu)
MA (2) MA42410B1 (hu)
MD (1) MD3319611T2 (hu)
MX (2) MX390302B (hu)
PE (1) PE20180483A1 (hu)
PH (2) PH12018500065B1 (hu)
PL (2) PL3319611T3 (hu)
PT (2) PT3319611T (hu)
RS (1) RS61718B1 (hu)
RU (2) RU2021100620A (hu)
SG (1) SG10202010553XA (hu)
SI (1) SI3319611T1 (hu)
SM (1) SMT202100226T1 (hu)
WO (1) WO2017007836A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
MX362544B (es) 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
US20190330259A1 (en) * 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
TW202444381A (zh) 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
EP4537847A3 (en) * 2017-01-13 2025-07-30 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
CN113667734B (zh) * 2021-07-16 2022-05-24 四川大学华西医院 Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途
US20240368214A1 (en) * 2021-08-25 2024-11-07 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
EP4430056A1 (en) * 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
JP2025504580A (ja) * 2022-01-28 2025-02-12 コレスゲン (シャンハイ) カンパニー リミテッド ステロイド系化合物、その製造方法及び使用
WO2024229297A1 (en) * 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Lymphatic system-targeting compounds
CN119371475B (zh) * 2023-07-27 2025-11-04 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
TW202508555A (zh) * 2023-07-27 2025-03-01 大陸商珂闌(上海)醫藥科技有限公司 甾類化合物、其製備方法和應用
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025221732A1 (en) * 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (hu) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
US4358406A (en) 1981-07-27 1982-11-09 Wisconsin Alumni Research Foundation 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
ATE45347T1 (de) 1985-05-30 1989-08-15 Taisho Pharmaceutical Co Ltd Vitamin d3-derivate.
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd 24,25−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0701444B1 (en) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
PT752860E (pt) 1994-02-14 2000-12-29 Euro Celtique Sa Androstanos e pregnanos para modulacao alosterica do receptor de gaba
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
CN1171114A (zh) 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
CA2223996A1 (en) 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
ATE254628T1 (de) 1995-06-23 2003-12-15 Novo Nordisk As Meiose regulierende verbindungen.
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
US5841272A (en) 1995-12-20 1998-11-24 Sundstrand Corporation Frequency-insensitive current sensor
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd 24,25−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) * 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
RU2243232C2 (ru) 1999-04-29 2004-12-27 Еро-Сельтик С.А. 3альфа-гидрокси-3бета-метоксиметил-21-гетероцикл-замещенные стероиды, фармацевтическая композиция, способ облегчения или профилактики бессонницы или погружения в наркоз
US6376530B1 (en) 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β-羟基-5-胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25-和24s,25-二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
DK1392713T3 (da) 2001-05-03 2008-02-18 Univ Chicago Lever-X-receptoragonister
JP2005508368A (ja) 2001-11-08 2005-03-31 ザ ユニバーシティー オブ シカゴ 高コレステロール濃度に関連した疾患の治療方法
CA2468989A1 (en) 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
NZ547344A (en) 2002-03-27 2007-11-30 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
GB0216621D0 (en) 2002-07-17 2002-08-28 Imaging Res Solutions Ltd Imaging compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
CA2506568A1 (en) 2002-11-22 2004-06-10 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
CA2585471A1 (en) 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
EP2097437B1 (en) 2006-11-21 2015-05-27 Umecrine Cognition AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換n−アリールピリジノン
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059961A2 (en) 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
JP2011505357A (ja) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びwntシグナル伝達を活性するためのオキシステロール
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
AU2009206580A1 (en) 2008-01-25 2009-07-30 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓x受容体アゴニスト
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) 2010-05-14 2010-06-30 Ge Healthcare Ltd Method of synthesis
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
SG2014010417A (en) 2011-10-07 2014-06-27 Takeda Pharmaceutical 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
PT2935307T (pt) 2012-12-18 2018-07-31 Univ Washington Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
EP3309166A3 (en) 2013-01-23 2018-08-22 Sphaera Pharma Pvt. Ltd. 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
JP2016514967A (ja) 2013-03-13 2016-05-26 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
MX362544B (es) 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
KR20160060688A (ko) 2013-09-25 2016-05-30 반 안델 리서치 인스티튜트 고도로 강력한 글루코코르티코이드
KR102476641B1 (ko) 2014-02-08 2022-12-09 제넨테크, 인크. 알츠하이머병의 치료 방법
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
US10016095B2 (en) * 2014-10-03 2018-07-10 Progressive International Corporation Salad spinner
RU2764702C2 (ru) 2014-10-07 2022-01-19 Сейдж Терапьютикс, Инк. Нейроактивные соединения и способы их применения
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
TW202444381A (zh) 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
AU2018288883B2 (en) 2017-06-23 2022-06-02 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
SG11202004329TA (en) 2017-11-10 2020-06-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
EP4333856A1 (en) 2021-05-04 2024-03-13 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
PE20180483A1 (es) 2018-03-07
CN108135912B (zh) 2021-07-02
CA2991214A1 (en) 2017-01-12
PT3828194T (pt) 2025-07-17
MX390302B (es) 2025-03-19
BR112018000129B1 (pt) 2024-01-09
RU2018104278A (ru) 2019-08-06
US20210145848A1 (en) 2021-05-20
US20190125764A1 (en) 2019-05-02
IL256710B1 (en) 2023-09-01
JP2018519351A (ja) 2018-07-19
JP2022120062A (ja) 2022-08-17
PH12021551134A1 (en) 2024-03-25
KR20180026743A (ko) 2018-03-13
US12268697B2 (en) 2025-04-08
RS61718B1 (sr) 2021-05-31
AU2021218228A1 (en) 2021-09-09
EP3828194B1 (en) 2025-04-16
KR20240137111A (ko) 2024-09-19
RU2018104278A3 (hu) 2019-10-31
PH12018500065B1 (en) 2022-11-04
IL305404A (en) 2023-10-01
CO2018000660A2 (es) 2018-07-10
SMT202100226T1 (it) 2021-05-07
NZ738847A (en) 2024-05-31
US10201550B2 (en) 2019-02-12
PL3828194T3 (pl) 2025-09-22
ES3035617T3 (en) 2025-09-05
SG10202010553XA (en) 2020-12-30
HRP20210526T1 (hr) 2021-05-28
KR102703602B1 (ko) 2024-09-06
MD3319611T2 (ro) 2021-06-30
CY1124496T1 (el) 2022-07-22
MA42410A (fr) 2018-05-16
DK3319611T3 (da) 2021-04-12
BR112018000129A2 (pt) 2018-09-04
MX376833B (es) 2025-03-07
HRP20210526T8 (hr) 2021-08-20
EP3319611A1 (en) 2018-05-16
AU2021218228B2 (en) 2023-11-16
BR122021005552B1 (pt) 2024-01-02
FI3828194T3 (fi) 2025-07-17
PL3319611T3 (pl) 2021-07-12
MX2020011449A (es) 2022-02-28
US20240277733A1 (en) 2024-08-22
NZ777726A (en) 2024-05-31
LT3319611T (lt) 2021-05-10
ES2865258T3 (es) 2021-10-15
AU2016289967B2 (en) 2021-09-09
EP3319611A4 (en) 2019-03-06
PH12018500065A1 (en) 2018-07-09
AU2024200268A1 (en) 2024-02-01
JP7602513B2 (ja) 2024-12-18
PT3319611T (pt) 2021-04-22
MA55097A (fr) 2022-01-05
SI3319611T1 (sl) 2021-08-31
MA42410B1 (fr) 2021-04-30
IL256710B2 (en) 2024-01-01
EP3828194A1 (en) 2021-06-02
CA2991214C (en) 2024-04-30
WO2017007836A1 (en) 2017-01-12
EP4609866A3 (en) 2025-10-22
US20180200267A1 (en) 2018-07-19
AU2016289967A1 (en) 2018-02-01
MX2018000282A (es) 2018-03-08
BR122023021450A2 (pt) 2023-12-26
JP2025026573A (ja) 2025-02-21
DK3828194T3 (da) 2025-06-30
CN108135912A (zh) 2018-06-08
EP3319611B1 (en) 2021-01-20
RU2744267C2 (ru) 2021-03-04
US10765685B2 (en) 2020-09-08
IL256710A (en) 2018-03-29
CN113292623A (zh) 2021-08-24
JP2021054864A (ja) 2021-04-08
RU2021100620A (ru) 2021-01-29
EP4609866A2 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
IL289976A (en) Oxysterols and methods of using them
IL286316A (en) New micro-dystrophins and related method of use
IL287916A (en) Molecules that bind pd-1 and methods of using them
IL266093A (en) Oxysterols and methods of using them
IL266092A (en) Oxysterols and methods of using them
IL256710A (en) Oxysterols and methods of using them
IL256179A (en) lag-3 binding molecules and methods of using them
IL250415B (en) Antibodies against pd-l and methods of using them
PT3436022T (pt) Oxisteróis e métodos de utilização dos mesmos
EP3157528A4 (en) Oxysterols and methods of use thereof
IL282482A (en) Variants of protoxin-II and methods of use
IL282508A (en) Variants of protoxin-II and methods of use
PT3397364T (pt) Elementos estruturados e métodos de utilização
GB201509977D0 (en) Dispensers and methods of use thereof
HK1247563A1 (en) Oxysterols and methods of use thereof
HK1247564A1 (en) Oxysterols and methods of use thereof
GB201416797D0 (en) Contianer and method of use thereof